AI assistant
EuroAPI — Capital/Financing Update 2023
Oct 24, 2023
1305_rns_2023-10-24_a68dc858-aa86-4b81-86d7-9c3a55d49593.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
EUROAPI increases the resources allocated to the liquidity contract with Kepler Cheuvreux
Paris – October 24, 2023 - In accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021, EUROAPI announced today that it has increased the resources allocated to the liquidity contract entrusted to Kepler Cheuvreux by 2 million euros (€ 2,000,000.00).
Following the addition of these resources, the position on October 24, 2023, is:
- 170,800 shares
- 2,263,204.73 euros
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.
Media Relations Contact: Laurence Bollack Mob.: +33 (0)6 81 86 80 19 [email protected]
Investor Relations Contact: Sophie Palliez-Capian Mob.: +33 (0)6 87 89 33 51 [email protected]